Bupropion.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing pharmacology, clinical indications, and safety data.
PubMed 17136226 · doi:10.1358/dot.2006.42.10.1025701
What was done
This narrative review summarizes the history, mechanisms of action, licensed indications, exploratory applications, and safety profile of bupropion. It compiles findings from existing literature regarding major depressive disorder, seasonal affective disorder, smoking cessation, ADHD, and anti-inflammatory properties.
What was found
Bupropion acts via dopamine and noradrenaline reuptake inhibition and inhibits CYP2D6. For smoking cessation, sustained-release bupropion demonstrates approximately 20% continuous abstinence at one year across diverse clinical groups (healthy smokers, cardiovascular disease, COPD, depression, and schizophrenia). Reported adverse effects include insomnia, headache, dry mouth, dizziness, and nausea, alongside risks associated with co-prescribing drugs that lower the seizure threshold.
Why it matters
This review synthesizes the clinical indications and pharmacology of bupropion, noting that despite demonstrated clinical and cost effectiveness for smoking cessation, its uptake has remained lower than nicotine replacement therapy.
Limits
The abstract describes a narrative review rather than a systematic review or meta-analysis; no search strategy, study selection criteria, risk of bias assessment, or pooled effect estimates with confidence intervals are provided.
Cited by
- supports Wellbutrin (bupropion) increases dopamine and norepinephrine broadly across the brain rather than targeting specific circuits.